Careers Contact Us

Partnership News & Events

Please read about our recent deals. We look forward to talking with and learning about you at upcoming conferences.


09/09/2008 Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria in Africa
09/03/2008 Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon for the Treatment of Alzheimer's and Huntington's Diseases
05/20/2008 FivePrime and Pfizer Enter Oncology and Diabetes Collaboration
04/16/2008 Pfizer and AVANT Enter into Licensing and Development Agreement for Novel Therapeutic Vaccine Candidate for Brain Cancer
03/03/2008 Pfizer to Acquire Serenex to Extend Oncology Pipeline and Access Novel Technology Platform
02/20/2008 Pfizer to Acquire Encysive Pharmaceuticals
01/16/2008 Pfizer and Scil Finalize Agreement for Novel Cartilage Growth Factor
01/07/2008 Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
01/07/2008 Pfizer and Taisho Finalize Agreement for Novel Schizophrenia Drug Candidate
12/18/2007 Pfizer to Acquire CovX to Extend Biotherapeutics Investment
12/05/2007 Pfizer and Adolor Enter into Exclusive Worldwide Collaboration to Develop and Commercialize Novel Pain Compounds
11/16/2007 Pfizer to Acquire Coley Pharmaceutical Group
10/30/2207 Taisho and Pfizer Sign a Letter of Intent for Taisho's Schizophrenia Drug Candidate
08/14/2007 Icagen Announces Alliance with Pfizer in Ion Channel-Focused Therapeutics for Pain and Related Disorders
07/26/2007 Hydra Biosciences and Pfizer Global Research & Development Sign Collaboration Agreement
04/26/2007 Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
12/20/2006 Kosan Announces License of Motilin Agonist Program to Pfizer
09/26/2006 Pfizer Expands Research Commitment to Ophthalmology Through Licensing Agreement With Quark Biotech
09/18/2006 Pfizer and TransTech Pharma Enter Into Agreement for the Development and Commercialization of RAGE Modulators
06/14/2006 Pfizer Enters Into Agreement with Bayer to License Compounds for Potential Treatment of Obesity, Diabetes and Related Disorders

We look forward to meeting you at these upcoming conferences.

JP Morgan Healthcare Conference

January 11-15 — San Francisco, USA
Download and Print Presentation (9.60 MB) PDF

BIO Asia

January 19-20 — Tokyo, Japan

Translational Medicine Alliance Forum

February 2-4 — Philadelphia, USA

BIO CEO and Investor Conference

February 9-11 — NYC, USA

BioSquare

March 9-11 — Lyon, France

BioNetwork East

March 16-18 — Naples, FL, USA

BIO Europe Spring

March 16-18 — Milan, Italy

NYBA — New York Biotechnology Association Annual Meeting

April 20-21 — NYC, USA

BIO International Convention

May 18-21 — Atlanta, Georgia, USA

Windhover/Pharmaceutical Strategic Alliances

March 9-11 — Lyon, France

BioSquare

September 23-25 — NYC, USA

BioPartnering Europe

October 13-15 — London, UK

Bio Europe

November 2-4 — Vienna, Austria

Conferences will be added as they are scheduled.


Text SizeAAA

"Pfizer is committed to flexible, transparent and mutually beneficial long-term relationships with its partners. By joining forces, we can bring quality therapies to patients worldwide. Let's work together for a healthier world."

—Bill Ringo, Senior Vice President,
Worldwide Business Development
Strategy & Innovation

Additional Points of Entry
Working with Pfizer